Clinical / Translational Investigator

The Immunotherapy Toxicities Program (iTox) at the Dana-Farber Cancer Institute (DFCI) is seeking a full-time Medical Oncologist (MD or MD/PhD) for a clinical / translational investigator leadership position to be based within the iTox Program and the clinical disease division of the selected candidate. This position is based in both the Department of Medical Oncology at DFCI and the Department of Medicine at Brigham and Women’s Hospital (BWH) and includes collaboration with other institutions affiliated with the Dana-Farber/Harvard Cancer Center and the Harvard Medical School.

iTox is an integrated program comprised of medical oncologists and specialists across multiple disciplines at both DFCI and BWH with the goal of optimizing immunotherapy-related adverse event care while further advancing our understanding of clinically relevant biology. This investigator will be part of the DFCI iTox program leadership, which includes a cadre of oncology clinicians, subspecialists and research investigators who can share knowledge and best practices and in so doing will grow a coordinated, dynamic, and efficient patient-centered program. The selected candidate will help build a clinical translational research program that focuses on the amelioration of immunotherapy-related adverse events (IRAEs) via novel therapeutic trials alongside the interrogation of clinical data and biological specimens utilizing the state-of-the-art resources of the Dana Farber/Harvard Cancer Center and affiliates. In addition, the successful candidate will be encouraged to collaborate with laboratory investigators with a focus on related biological pathways.

The chosen candidate will devote 50% effort to patient care and will be responsible for teaching fellows and students in the outpatient setting. The academic appointment will be at the Instructor/ Assistant/ Associate Professor level at Harvard Medical School and determined by the applicant's credentials. Salary and benefits will be competitive with other institutions. Applicants should have an MD or equivalent and should be board certified in Internal Medicine and board certified or board eligible in Medical Oncology.

Interested candidates should submit a letter of interest by email along with their CV and the names and email addresses of three references to:

Dr. John Koreth, MBBS DPhil
Chair-Search Committee
Department of Medical Oncology
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston MA 02215
attn: katie_kupferberg@dfci.harvard.edu

Dana-Farber Cancer Institute is an NCI-designated Comprehensive Cancer Center. We are an equal opportunity employer and all qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, disability status, protected veteran status, gender
identity, sexual orientation, pregnancy and pregnancy-related conditions or any other characteristic protected by law.

Women and minority candidates are particularly encouraged to apply.